Criterion Capital Advisors, LLC Astrazeneca PLC Transaction History
Criterion Capital Advisors, LLC
- $159 Billion
- Q3 2024
A detailed history of Criterion Capital Advisors, LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Criterion Capital Advisors, LLC holds 59 shares of AZN stock, worth $3,872. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59
Previous 59
-0.0%
Holding current value
$3,872
Previous $4.6 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AZN
# of Institutions
1,359Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.13 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.76 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.44 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.42 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.3MShares$1.27 Billion0.43% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $203B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...